|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy显示文摘AIM To determine influence of neoadjuvant-chemotherapy(NAC) over tumor-infiltrating-lymphocytes(TIL) intriple-negative-breast-cancer(TNBC).METHODS TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays(TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response(pCR)(P = 0.0251) and outcome(P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections(ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. PostNAC lesions with pC R had similar TIL levels than those without pCR(P = 0.6331). NAC produced a TIL decrease in full-face sections(P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival(DFS). Higher counts of CD3 in pre-NAC samples had longer overallsurvival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR.CONCLUSION TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related. | Carlos A Castaneda Elizabeth Mittendorf Sandro Casavilca Yun Wu Miluska Castillo Patricia Arboleda Teresa Nunez Henry Guerra Carlos Barrionuevo Ketty Dolores-Cerna Carolina Belmar-Lopez Julio Abugattas Gabriela Calderon Miguel De La Cruz Manuel Cotrina Jorge Dunstan Henry L Gomez Tatiana Vidaurre | 2016 | World Journal of Clinical Oncology2016，7，5： | 6 |
| 2 | Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy显示文摘AIM To investigate the survival impact of clinicopathological factors, including pathological complete response(p CR) and tumor-infiltrating lymphocytes(s TIL) levels according to subtypes, in breast cancer(BC) patients who received neo-adjuvant chemotherapy(NAC).METHODS We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. s TIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preN AC core biopsy. p CR was considered in the absence of infiltrating cancer cells in primary tumor and axillary lymph nodes. Analysis of statistical association between clinical pathological features, s TIL, p CR and survival were carried out using SPSSvs19.RESULTS Median age was 49 years(range 24-84 years) and the most frequent clinical stage was ⅢB(58.3%). Luminal A, Luminal B, HER2-enriched and(triple-negative) TN phenotype was found in 24.6%, 37.9%, 17.7% and 19.8%, respectively. p CR was observed in 11% and median percentage of s TIL was 40%(2%-95%) in the whole population. p CR was associated to Ct1-2(P = 0.045) and to high s TIL(P = 0.029) in the whole population. There was a slight trend towards significance for s TIL(P = 0.054) in Luminal A. s TIL was associated with grade Ⅲ(P < 0.001), no-Luminal A subtype(P < 0.001), RE-negative(P < 0.001), PgR-negative(P < 0.001), HER2-positive(P = 0.002) and p CR(P = 0.029) in the whole population. Longer disease-free survival was associated with grade Ⅰ-Ⅱ(P = 0.006), cN 0(P < 0.001), clinical stage Ⅱ(P = 0.004), ER-positive(P < 0.001), Pg R-positive(P < 0.001), luminal A(P < 0.001) and p CR(P = 0.002). Longer disease-free survival was associated with grade Ⅰ-Ⅱ in Luminal A(P < 0.001), N0-1 in Luminal A(P = 0.045) and TNBC(P = 0.01), clinical stage Ⅱ in Luminal A(P = 0.003) and TNBC(P = 0.038), and pC R in TNBC(P < 0.001). Longer overall survival was associated with grade Ⅰ-Ⅱ(P < 0.001), ER-positive(P < 0.001), PgR-positive(P < 0.001), Luminal A(P < 0.001), cN 0(P = 0.002) and p CR(P = 0.002) in the whole population. Overall survival was associated with clinical stage Ⅱ(P = 0.017) in Luminal A, older age(P = 0.042) in Luminal B, and pC R in TNBC(P = 0.005).CONCLUSION Predictive and prognostic values of clinicopathological features, like p CR and s TIL, differ depending on the evaluated molecular subtype. | Marco Galvez Carlos A Castaneda Joselyn Sanchez Miluska Castillo Lia Pamela Rebaza Gabriela Calderon Miguel De La Cruz Jose Manuel Cotrina Julio Abugattas Jorge Dunstan Henry Guerra Omar Mejia Henry L Gomez | 2018 | World Journal of Clinical Oncology2018，9，2： | 4 |
| 3 | Organizational Commitment: The Utility of an Integrative Definition 显示文摘 | Dunham R B Grube J A Castaneda M B | 1994 | Journal of Ap- plied Psychology1994，79，3： | 1 |
| 4 | Organizational Commitment : The Utility of an Integrative Definition 显示文摘 | Dunham R B Grube J A Castaneda M B | 1994 | Journal of Applied Psychology1994，79，3： | 1 |
| 5 | Nucleation and growth of mineralized bone matrix on silk-hydroxyapatite composite scaffolds显示文摘 | Bhumiratana S Grayson W L Castaneda A | 2011 | Biomaterials2011，32，11： | 1 |
| 6 | A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults 显示文摘 | Castaneda AE Tuulio-Henriksson A Marttunen M | 2008 | J Affect Disord2008，106，12： | 1 |
| 7 | Oligosaccharides released by pectinase treatment of citrus on seedlings are elicitors of the plant response显示文摘 | Roco A Castaneda P Perez L M | 1993 | Phytochemistry1993，，6： | 1 |
| 8 | Impact of problem-based learning on the cognitive processes of medical students显示文摘 | Urrutia A M E Hamui-Sutton A Castaneda F S | 2011 | Gac Med Mex2011，147，5： | 1 |
| 9 | Surgical management of multiple ventricular septal defects 显示文摘 | KIRKLIN J K CASTANEDA A R KEANE J F et at | 1980 | J Thorac Cardiovasc Surg1980，80，4： | 1 |
| 10 | Thrombosed synthetic hemodialysis access fistulas: failure of fibrinolytic therapy 显示文摘 | Young A T Hunter D W Castaneda Zuniga W R | 1985 | Radiology1985，154，3： | 1 |
| 11 | Olerance to vancomycin in a multiresistant,Colombian isolate of Streptococcus pneumoniae显示文摘 | Hidalgo M Castaneda E Arias C A | 2003 | J Antimicrob Chemother2003，52，2： | 1 |
| 12 | Activation of mitochondrial apoptotic pathways in human renal allografts after ischemia reperfusion injury 显示文摘 | Castaneda MP Swiatecka - Urban A Mitsnefes MM | 2003 | Transplantation2003，76，1： | 1 |
| 13 | Nephrostolithotomy:Percutaneous Techniques for Urinary Calculus Removal显示文摘 | Castaneda Zunign W R Clayman R Smith A | 2002 | J Urol2002，167，2： | 1 |
| 14 | Scan Blindness Free Phased Array DesignUsing PBG Materials显示文摘 | Zhang Li-jun Castaneda J A Alexopoules N G | 2004 | IEEE Transactions on Antennas and Propagation2004，52，8： | 1 |
| 15 | Results of a phase Ⅲ clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified显示文摘 | Aviles A Castaneda C Neri N | 2008 | Med Oncol2008，25，3： | 1 |
| 16 | Origin of pulmonary artery branch from ascending aorta显示文摘 | Penkoske P A Castaneda A R Fyler D C | | 0，，07： | 1 |
| 17 | Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease显示文摘 | Rabinovitch M Haworth S Castaneda A | 1978 | Cir- culation1978，58，6： | 1 |
| 18 | Nephrostolithotmy:percutaneous techniques for urinarycalculus removal显示文摘 | Castaneda Zuniga W R Clayman R Smith A | 2002 | J Urol2002，167，2： | 1 |
| 19 | Performance of multipath routing for on-demand protocols in mobile ad hoc nctworks显示文摘 | Nasipuri A Castaneda R Das S R | 2001 | ACM/Kluwer Mobile Networks and Applications (MONET)2001，6，4： | 1 |
| 20 | Performance of multi - path routing for on-demand protocols in mobile ad hoc networks显示文摘 | Nasipuri A Castaneda R Das S R | 2001 | ACM Mobile Networks and Applications ( MONET)2001，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员